Thenappan Thenappan

9.1k total citations · 2 hit papers
164 papers, 5.8k citations indexed

About

Thenappan Thenappan is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Thenappan Thenappan has authored 164 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 70 papers in Cardiology and Cardiovascular Medicine and 25 papers in Surgery. Recurrent topics in Thenappan Thenappan's work include Pulmonary Hypertension Research and Treatments (95 papers), Cardiovascular Function and Risk Factors (32 papers) and Heart Failure Treatment and Management (26 papers). Thenappan Thenappan is often cited by papers focused on Pulmonary Hypertension Research and Treatments (95 papers), Cardiovascular Function and Risk Factors (32 papers) and Heart Failure Treatment and Management (26 papers). Thenappan Thenappan collaborates with scholars based in United States, India and Canada. Thenappan Thenappan's co-authors include Stephen L. Archer, Mardi Gomberg‐Maitland, Sanjiv J. Shah, Stuart Rich, John Ryan, Ε. Kenneth Weir, Kurt W. Prins, Mark L. Ormiston, Marc Pritzker and G. Parthipan and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Thenappan Thenappan

154 papers receiving 5.6k citations

Hit Papers

Pulmonary arterial hypertension: pathogenesis and clinica... 2018 2026 2020 2023 2018 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pulmonary arterial hypertension: pathogenesis and clinical management
    2018 676 citations Thenappan Thenappan, John Ryan et al. profile →
  2. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
    2021 336 citations Thenappan Thenappan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thenappan Thenappan United States 36 3.9k 2.4k 1.0k 620 506 164 5.8k
Steeve Provencher Canada 53 6.2k 1.6× 3.4k 1.4× 2.0k 1.9× 874 1.4× 617 1.2× 187 8.3k
Ekkehard Grünig Germany 50 9.4k 2.4× 6.7k 2.8× 1.1k 1.1× 789 1.3× 875 1.7× 253 11.5k
Zhi‐Cheng Jing China 39 8.6k 2.2× 5.8k 2.4× 1.3k 1.3× 1.1k 1.8× 1.0k 2.0× 221 10.6k
Eckhard Mayer Germany 50 7.1k 1.8× 5.4k 2.2× 319 0.3× 1.0k 1.6× 578 1.1× 188 8.7k
Marion Delcroix Belgium 48 9.6k 2.5× 6.6k 2.8× 693 0.7× 1.3k 2.2× 1.3k 2.6× 266 11.7k
Howard Leong‐Poi Canada 41 861 0.2× 1.8k 0.8× 1.6k 1.5× 883 1.4× 440 0.9× 161 7.0k
Christopher Christophi Australia 38 1.2k 0.3× 956 0.4× 964 0.9× 2.3k 3.8× 634 1.3× 198 5.7k
Ronald J. Oudiz United States 48 10.3k 2.7× 7.7k 3.2× 543 0.5× 1.1k 1.8× 1.1k 2.1× 127 11.7k
Michael Burt United States 59 5.6k 1.4× 868 0.4× 963 0.9× 2.7k 4.4× 700 1.4× 181 9.7k
Jean‐Bernard Durand United States 34 949 0.2× 4.4k 1.9× 1.5k 1.4× 659 1.1× 309 0.6× 133 7.0k

Countries citing papers authored by Thenappan Thenappan

Since Specialization
Citations

This map shows the geographic impact of Thenappan Thenappan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thenappan Thenappan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thenappan Thenappan more than expected).

Fields of papers citing papers by Thenappan Thenappan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thenappan Thenappan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thenappan Thenappan. The network helps show where Thenappan Thenappan may publish in the future.

Co-authorship network of co-authors of Thenappan Thenappan

This figure shows the co-authorship network connecting the top 25 collaborators of Thenappan Thenappan. A scholar is included among the top collaborators of Thenappan Thenappan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thenappan Thenappan. Thenappan Thenappan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prisco, Sasha Z., Felipe Kazmirczak, B. Kremer, et al.. (2025). Lactobacillus Restructures the Micro/Mycobiome to Combat Inflammation-Mediated Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. Circulation Heart Failure. 18(7). e012524–e012524. 4 indexed citations
2.
Sahay, Sandeep, Murali M. Chakinala, Nick H. Kim, et al.. (2024). Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective. American Journal of Respiratory and Critical Care Medicine. 210(5). 581–592. 13 indexed citations
3.
Baird, Grayson L., David B. Badesch, Teresa De Marco, et al.. (2023). Medication Non-adherence and Health-related Outcomes in Patients With Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR). A1186–A1186. 1 indexed citations
4.
Kazmirczak, Felipe, et al.. (2023). Abstract 13007: Ketone Bodies for Right Ventricular Failure: A Unique Therapeutic Opportunity. Circulation. 148(Suppl_1).
5.
Lutsey, Pamela L., Thenappan Thenappan, Kurt W. Prins, et al.. (2022). Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database. Journal of the American Heart Association. 11(14). e024358–e024358. 10 indexed citations
6.
Benza, Raymond L., David Langleben, Anna R. Hemnes, et al.. (2022). Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review. 31(166). 220061–220061. 10 indexed citations
7.
Garry, Jonah, Nicholas A. Kolaitis, Richard A. Kronmal, et al.. (2022). Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). The Journal of Heart and Lung Transplantation. 41(12). 1808–1818. 5 indexed citations
8.
Prisco, Sasha Z., Kurt W. Prins, Christopher Staley, et al.. (2022). Pulmonary Arterial Hypertension Patients Have a Proinflammatory Gut Microbiome and Altered Circulating Microbial Metabolites. American Journal of Respiratory and Critical Care Medicine. 207(6). 740–756. 46 indexed citations
9.
Rose, Lauren, Kurt W. Prins, Stephen L. Archer, et al.. (2018). Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. The Journal of Heart and Lung Transplantation. 38(2). 145–155. 47 indexed citations
10.
Anand, Vidhu, Sushil Kumar Garg, Ryan J. Koene, & Thenappan Thenappan. (2016). Abstract 17286: National Trends in Hospital Readmission Rates in Congestive Heart Failure Patients. Circulation. 134. 2 indexed citations
11.
Prins, Kurt W., Ε. Kenneth Weir, Stephen L. Archer, et al.. (2016). Pulmonary Pulse Wave Transit Time is Associated with Right Ventricular–Pulmonary Artery Coupling in Pulmonary Arterial Hypertension. Pulmonary Circulation. 6(4). 576–585. 26 indexed citations
12.
Thenappan, Thenappan, et al.. (2014). β-Blocker Therapy Is Not Associated With Adverse Outcomes in Patients With Pulmonary Arterial Hypertension. Circulation Heart Failure. 7(6). 903–910. 35 indexed citations
13.
Marsboom, Glenn, Péter T. Tóth, John Ryan, et al.. (2012). Dynamin-Related Protein 1–Mediated Mitochondrial Mitotic Fission Permits Hyperproliferation of Vascular Smooth Muscle Cells and Offers a Novel Therapeutic Target in Pulmonary Hypertension. Circulation Research. 110(11). 1484–1497. 387 indexed citations
14.
Marsboom, Glenn, Christian Wietholt, Chad R. Haney, et al.. (2012). Lung 18F-Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 185(6). 670–679. 143 indexed citations
15.
Piao, Lin, et al.. (2012). CHRONIC INHIBITION OF PYRUVATE DEHYDROGENASE KINASE WITH DICHLOROACETATE, IMPROVES CARDIAC METABOLISM AND FUNCTION IN RIGHT VENTRICULAR HYPERTROPHY IN FAWN-HOODED RATS. Journal of the American College of Cardiology. 59(13). E1604–E1604. 2 indexed citations
16.
Thenappan, Thenappan, Glenn Marsboom, Yong-Hu Fang, et al.. (2010). A Central Role for CD68(+) Macrophages in Hepatopulmonary Syndrome: Reversal by Macrophage Depletion. American Journal of Respiratory and Critical Care Medicine. 183(8). 1080–1091. 149 indexed citations
17.
Sweiss, Nadera, Thenappan Thenappan, Roberto F. Machado, et al.. (2010). Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis. Current Rheumatology Reports. 12(1). 8–18. 23 indexed citations
18.
Thenappan, Thenappan, Sanjiv J. Shah, Stuart Rich, et al.. (2009). Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. European Respiratory Journal. 35(5). 1079–1087. 360 indexed citations
19.
Thenappan, Thenappan, et al.. (2006). Dielectric studies of H-bonded complexes of benzamide and nicotinamide with alcohols. Indian Journal of Pure & Applied Physics. 44(4). 339–344. 5 indexed citations
20.
Thenappan, Thenappan, et al.. (2004). Studies on fluid structure and molecular interactions of amides. Indian Journal of Pure & Applied Physics. 42(6). 435–439. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steeve Provencher Breakdown of academic impact, for papers by Ekkehard Grünig Breakdown of academic impact, for papers by Zhi‐Cheng Jing Breakdown of academic impact, for papers by Eckhard Mayer Breakdown of academic impact, for papers by Marion Delcroix Breakdown of academic impact, for papers by Howard Leong‐Poi Breakdown of academic impact, for papers by Christopher Christophi Breakdown of academic impact, for papers by Ronald J. Oudiz Breakdown of academic impact, for papers by Michael Burt Breakdown of academic impact, for papers by Jean‐Bernard Durand
Rankless by CCL
2026